---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-006524"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:43:36.887670+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio closes $575M 1.75% convertible notes due 2031; refinances Blue Owl secured debt

## Summary
- Issued $575M aggregate principal of 1.75% convertible senior notes due March 1, 2031.
- Net proceeds of ~$563M; used $48.3M to repurchase 1.4M shares at $34.35.
- Repaid and terminated Financing Agreement with Blue Owl, eliminating ~$51.5M annual interest.
- Notes are senior unsecured; conversion price ~$49.81 per share (45% premium).
- May not redeem before March 6, 2028; can redeem after if stock exceeds 130% of conversion price.

## SEC filing metadata
- accession: 0001140361-25-006524
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036125006524/0001140361-25-006524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036125006524/ef20044715_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-006524
- JSON: https://secwatch.observer/filing/0001140361-25-006524.json
- Plain text: https://secwatch.observer/filing/0001140361-25-006524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.